黑素瘤疫苗：过去喜忧参半，未来充满希望。
Melanoma vaccines: mixed past, promising future.
机构信息
John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
出版信息
Surg Clin North Am. 2014 Oct;94(5):1017-30, viii. doi: 10.1016/j.suc.2014.07.005. Epub 2014 Aug 7.
Abstract
Cancer vaccines were one of the earliest forms of immunotherapy to be investigated. Past attempts to vaccinate against cancer, including melanoma, have mixed results, showing the complexity of what was believed to be a simple concept. However, several recent successes and the combination of improved knowledge of tumor immunology and the advent of new immunomodulators make vaccination a promising strategy for the future.
摘要
癌症疫苗是最早被研究的免疫疗法之一。过去针对癌症（包括黑色素瘤）的疫苗接种尝试结果喜忧参半，这表明人们原本认为简单的概念其实非常复杂。然而，最近的一些成功案例以及肿瘤免疫学知识的提高和新型免疫调节剂的出现，使得疫苗接种成为未来有前途的策略。
相似文献
1
Melanoma vaccines: mixed past, promising future.
Surg Clin North Am. 2014 Oct;94(5):1017-30, viii. doi: 10.1016/j.suc.2014.07.005. Epub 2014 Aug 7.
2
Prediction of response to anticancer immunotherapy using gene signatures.
J Clin Oncol. 2013 Jul 1;31(19):2369-71. doi: 10.1200/JCO.2013.49.2157. Epub 2013 May 28.
3
Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Expert Rev Vaccines. 2003 Jun;2(3):353-68. doi: 10.1586/14760584.2.3.353.
4
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Am J Clin Oncol. 2006 Aug;29(4):352-60. doi: 10.1097/01.coc.0000217877.78473.a4.
5
Melanoma vaccine momentum spurs interest, investment.
J Natl Cancer Inst. 2000 Aug 2;92(15):1205-7. doi: 10.1093/jnci/92.15.1205.
6
Vaccination and melanoma risk.
Int J Cancer. 2002 Nov 1;102(1):96-7. doi: 10.1002/ijc.10671.
7
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000544.
8
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.
9
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.
10
Peptide-based vaccines for cancer immunotherapy.
Expert Opin Biol Ther. 2004 Feb;4(2):181-98. doi: 10.1517/14712598.4.2.181.
引用本文的文献
1
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
J Clin Oncol. 2025 May 10;43(14):1685-1694. doi: 10.1200/JCO-24-02219. Epub 2025 Mar 6.
2
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Clin Exp Med. 2024 Dec 25;25(1):24. doi: 10.1007/s10238-024-01541-7.
3
Immunotherapy and delivery systems for melanoma.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2394252. doi: 10.1080/21645515.2024.2394252. Epub 2024 Sep 17.
4
Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines.
Vaccines (Basel). 2023 Jun 29;11(7):1172. doi: 10.3390/vaccines11071172.
5
Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives.
Front Oncol. 2022 Jan 5;11:727027. doi: 10.3389/fonc.2021.727027. eCollection 2021.
6
Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines.
Cancers (Basel). 2021 Dec 8;13(24):6189. doi: 10.3390/cancers13246189.
7
The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review).
Biomed Rep. 2021 Oct;15(4):86. doi: 10.3892/br.2021.1462. Epub 2021 Aug 17.
8
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications.
Front Immunol. 2021 Aug 10;12:705999. doi: 10.3389/fimmu.2021.705999. eCollection 2021.
9
Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.
Front Pharmacol. 2021 May 10;12:679602. doi: 10.3389/fphar.2021.679602. eCollection 2021.
10
Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.
Integr Cancer Ther. 2021 Jan-Dec;20:1534735421990078. doi: 10.1177/1534735421990078.
本文引用的文献
1
Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
Expert Opin Biol Ther. 2014 Jul;14(7):955-67. doi: 10.1517/14712598.2014.902928. Epub 2014 Mar 26.
2
Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.
Mol Clin Oncol. 2013 May;1(3):466-472. doi: 10.3892/mco.2013.97. Epub 2013 Mar 20.
3
Molecular and genetic diversity in the metastatic process of melanoma.
J Pathol. 2014 May;233(1):39-50. doi: 10.1002/path.4318. Epub 2014 Jan 27.
4
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.
5
Melanoma, version 2.2013: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw. 2013 Apr 1;11(4):395-407. doi: 10.6004/jnccn.2013.0055.
6
Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10(+) IFN-γ(+)-producing CD4(+) T cells.
Immunol Res. 2013 May;56(1):1-8. doi: 10.1007/s12026-012-8382-7.
7
Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.
J Immunother. 2012 Nov-Dec;35(9):716-20. doi: 10.1097/CJI.0b013e31827457bd.
8
Abscopal effect in a patient with melanoma.
N Engl J Med. 2012 May 24;366(21):2035; author reply 2035-6. doi: 10.1056/NEJMc1203984.
9
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
Cancer J. 2011 Sep-Oct;17(5):343-50. doi: 10.1097/PPO.0b013e318233e5b2.
10
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
J Clin Oncol. 2011 Jul 20;29(21):2924-32. doi: 10.1200/JCO.2010.33.8053. Epub 2011 Jun 20.
Zotero 插件